Clinical Study to Evaluate the Safety and Efficacy of U87 CART in Treatment of Advanced Solid Tumor
Latest Information Update: 31 May 2024
At a glance
- Drugs Cyclophosphamide (Primary) ; U 87 (Primary) ; Interleukin-2
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Shanghai Unicar-Therapy Bio-medicine Technology
- 28 Nov 2023 Planned primary completion date changed from 8 Oct 2023 to 31 Dec 2024.
- 13 Nov 2022 New trial record